Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report)’s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.97 and traded as low as $2.73. Galmed Pharmaceuticals shares last traded at $2.97, with a volume of 31,645 shares traded.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday, October 9th. They issued a “sell” rating for the company.
Get Our Latest Report on Galmed Pharmaceuticals
Galmed Pharmaceuticals Price Performance
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- Investing in Construction Stocks
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- How Technical Indicators Can Help You Find Oversold StocksÂ
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- 3 REITs to Buy and Hold for the Long Term
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.